Cullinan Associates Inc Amgen Inc Transaction History

Cullinan Associates Inc

$1.81 Billion
Q3 2024

A detailed history of Cullinan Associates Inc transactions in Amgen Inc stock. As of the latest transaction made, Cullinan Associates Inc holds 47,903 shares of AMGN stock, worth $12.7 Million. This represents 0.85% of its overall portfolio holdings.

Number of Shares

47,903

Previous 51,014 6.1%

Holding current value

$12.7 Million

Previous $15.9 Million 3.17%

% of portfolio

0.85%

Previous 0.91%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 23, 2024	SELL	$309.38 - $337.38 $962,481 - $1.05 Million	-3,111 Reduced 6.1%	47,903 $15.4 Million
Q2 2024 Jul 10, 2024	SELL	$262.75 - $319.31 $32.5 Million - $39.5 Million	-123,606 Reduced 70.79%	51,014 $15.9 Million
Q1 2024 Apr 18, 2024	BUY	$268.87 - $324.56 $5.04 Million - $6.08 Million	18,733 Added 12.02%	174,620 $49.6 Million
Q4 2023 Jan 24, 2024	SELL	$255.7 - $288.46 $2.8 Million - $3.16 Million	-10,968 Reduced 6.57%	155,887 $44.9 Million
Q3 2023 Oct 11, 2023	SELL	$218.65 - $271.46 $9.53 Million - $11.8 Million	-43,567 Reduced 20.7%	166,855 $44.8 Million
Q2 2023 Jul 14, 2023	SELL	$214.27 - $253.37 $324,619 - $383,855	-1,515 Reduced 0.71%	210,422 $46.7 Million
Q1 2023 Apr 05, 2023	BUY	$225.79 - $275.2 $2.07 Million - $2.52 Million	9,173 Added 4.52%	211,937 $51.2 Million
Q4 2022 Jan 11, 2023	SELL	$229.03 - $291.01 $118,408 - $150,452	-517 Reduced 0.25%	202,764 $53.3 Million
Q3 2022 Oct 19, 2022	BUY	$224.46 - $253.15 $164,304 - $185,305	732 Added 0.36%	203,281 $45.8 Million
Q2 2022 Jul 08, 2022	BUY	$230.71 - $256.74 $791,566 - $880,874	3,431 Added 1.72%	202,549 $49.3 Million
Q1 2022 Apr 21, 2022	BUY	$219.27 - $242.57 $354,559 - $392,235	1,617 Added 0.82%	199,118 $48.2 Million
Q4 2021 Jan 07, 2022	BUY	$198.88 - $227.6 $864,133 - $988,922	4,345 Added 2.25%	197,501 $44.4 Million
Q3 2021 Oct 08, 2021	BUY	$212.27 - $248.7 $4.48 Million - $5.25 Million	21,128 Added 12.28%	193,156 $41.1 Million
Q2 2021 Jul 07, 2021	BUY	$233.58 - $259.14 $2.61 Million - $2.89 Million	11,171 Added 6.94%	172,028 $41.9 Million
Q1 2021 Apr 20, 2021	SELL	$221.91 - $258.6 $1.04 Million - $1.22 Million	-4,708 Reduced 2.84%	160,857 $40 Million
Q4 2020 Jan 14, 2021	SELL	$216.38 - $257.67 $887,158 - $1.06 Million	-4,100 Reduced 2.42%	165,565 $38.1 Million
Q3 2020 Oct 09, 2020	SELL	$234.65 - $260.95 $645,287 - $717,612	-2,750 Reduced 1.59%	169,665 $43.1 Million
Q2 2020 Jul 07, 2020	BUY	$197.81 - $242.74 $24.9 Million - $30.6 Million	125,988 Added 271.37%	172,415 $40.7 Million
Q1 2020 Apr 01, 2020	SELL	$182.24 - $241.7 $697,979 - $925,711	-3,830 Reduced 7.62%	46,427 $9.41 Million
Q4 2019 Jan 15, 2020	BUY	$189.21 - $243.2 $121,283 - $155,891	641 Added 1.29%	50,257 $12.1 Million
Q3 2019 Oct 01, 2019	SELL	$174.11 - $208.62 $341,255 - $408,895	-1,960 Reduced 3.8%	49,616 $9.6 Million
Q2 2019 Jul 16, 2019	BUY	$166.7 - $195.41 $111,855 - $131,120	671 Added 1.32%	51,576 $9.5 Million
Q1 2019 Apr 30, 2019	SELL	$180.87 - $203.88 $231,513 - $260,966	-1,280 Reduced 2.45%	50,905 $9.67 Million
Q4 2018 Jan 11, 2019	SELL	$178.4 - $208.25 $77,247 - $90,172	-433 Reduced 0.82%	52,185 $10.2 Million
Q3 2018 Oct 19, 2018	SELL	$185.29 - $208.89 $1.48 Million - $1.67 Million	-8,007 Reduced 13.21%	52,618 $10.9 Million
Q2 2018 Jul 09, 2018	SELL	$166.05 - $186.51 $5.86 Million - $6.58 Million	-35,281 Reduced 36.79%	60,625 $11.2 Million
Q1 2018 Apr 27, 2018	SELL	$169.43 - $198.0 $138,932 - $162,360	-820 Reduced 0.85%	95,906 $16.4 Million
Q4 2017 Jan 17, 2018	SELL	$168.79 - $188.59 $173,178 - $193,493	-1,026 Reduced 1.05%	96,726 $16.8 Million
Q3 2017 Oct 16, 2017	BUY	$167.29 - $191.0 $16.4 Million - $18.7 Million	97,752	97,752 $18.2 Million

Others Institutions Holding AMGN

# of Institutions

3,126

Shares Held

409M

Call Options Held

7.56M

Put Options Held

7.2M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $142B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cullinan Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cullinan Associates Inc with notifications on news.

Account

Cullinan Associates Inc Amgen Inc Transaction History